Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
FDA approvals
4 regulatory events affecting GLP-1 medications in 2023.
Tirzepatide approved for chronic weight management at doses to 15 mg/week. SURMOUNT-1 trial showed ~22% body-weight reduction at 72 weeks.
Read on fda.gov →FDA updated Ozempic, Wegovy, and Saxenda labels to include ileus (intestinal blockage) as adverse reaction following postmarket reports.
Read on fda.gov →FDA issued public alert about adverse events from compounded semaglutide — flagged use of semaglutide salt forms (sodium, acetate) not present in FDA-approved products.
Read on fda.gov →Sanofi discontinued Adlyxin in the US market for commercial reasons.
Read on fda.gov →